ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04201262
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
- Conditions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04202341
- Locations
- 🇮🇹
Clinical Trial Site, Naples, Italy
🇺🇸Clincal Trial Site, Gainesville, Florida, United States
Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04195763
- Locations
- 🇺🇸
Xcenda, LLC, Palm Harbor, Florida, United States
Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04189315
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04170023
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04155424
- Locations
- 🇪🇸
Clinical Trial Site, Sevilla, Spain
🇪🇸Research Site, Esplugues de Llobregat, Spain
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT03920293
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03759366
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03748823
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT03661528
- Locations
- 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath